Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Inclusion Criteria: * Male or female, 55 years of age or older * Former smokers and current enrolled in LDCT lung cancer screening or those who are detected using a regular CT, and have Lung-RADS 3 category lesion(s), that would get a 6 month f/u LDCT or regular CT based on Lung-RADS recommendations or former and current smokers enrolled in LDCT lung cancer screening, or regular CT and have Lung-RADS 2 category lesions with part-solid or non-solid lung nodule ≥4mm mean diameter detected during screening LDCT or regular CT scans * History of cigarette smoking with ≥ 20 pack years * All current smokers should accept to receive smoking cessation * Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1 * Able to swallow study pills * Able to undergo CT * Not allergic to components of study agents * Willing to discontinue current vitamin/mineral supplement use containing components of study agents. A standard multivitamin supplement provided for the study * Willing to comply with proposed visit and treatment schedule * Able to understand and willing to sign a written informed consent document * Participants must have normal organ and marrow function * Willing to use contraception during the intervention period of 6 months (males and females) * Not pregnant or lactating nor planning to become pregnant or lactate during the 6 month study intervention period.. Exclusion Criteria: * Invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell carcinoma) diagnosed within the last 2 years * Inability to undergo CT * Newly diagnosed nodule meeting Lung-RADS 4 criteria * Have taken doxycycline or tetracycline less than or equal to 2 weeks * Females- pregnant or lactating (throughout the duration of intervention of 6 months) * Unwilling to use effective form of birth control (Males and females) (throughout the duration of intervention of 6 months).